Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in new study

The vaccine, built on the same mRNA platform used for COVID‑19 shots, was tailored to each patient's tumor and added to standard post‑surgery therapy.

By Felo News Desk · Published Fri, 23 Oct 2026 14:06:28 GMT

A joint study by Moderna and Merck reports that a personalized mRNA vaccine lowered the two‑year risk of melanoma returning by 42% when given after surgery, according to the researchers.

What happened

The international trial enrolled melanoma patients who had undergone surgical removal of their tumors. Each participant received a custom‑made vaccine, named intismeran, designed to match the genetic profile of their cancer. The vaccine was administered alongside the usual post‑operative treatment regimen. After two years, the group that received intismeran showed a 42% lower recurrence rate compared with patients who received standard care alone.

What the reports add

Both the AP News brief and the New York Post note that intismeran uses the same Nobel‑prize‑winning mRNA technology that powered COVID‑19 vaccines. The AP piece adds that experimental mRNA vaccines are also being tested for lung, kidney and pancreatic cancers, and that experts not involved with the study said its success “bolsters the field.” The New York Post provides additional details: the trial involved more than 1,100 high‑risk melanoma patients, all of whom received Merck’s immunotherapy Keytruda as standard follow‑up therapy; participants were randomly assigned to receive either the custom‑brewed vaccine or a placebo; the vaccine regimen consisted of nine doses given three weeks apart; the detailed results were slated for presentation at the European Society of Medical Oncology meeting in Madrid, but data were leaked publicly on Thursday, prompting an earlier full release.

What was said

“The field has been looking for a win and I think this one is a big one,” said Dr. Hussein Tawbi of MD Anderson Cancer Center in Houston, one of the researchers in the international study (AP News).

“This is a new frontier,” said Karen Knudsen, CEO of the Parker Institute, adding “It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers” (New York Post).

“It’s a big step forward for science, for oncology, because this vaccine will apply to many different cancers,” said Dr. Michael Atkins, deputy director of Georgetown University’s Lombardi Comprehensive Cancer Center (New York Post).

How it came about

The vaccine builds on the mRNA platform that proved effective in the global COVID‑19 response. Earlier Felo coverage on cancer advances, such as the September 18 article on modern lung‑cancer treatments (Modern Lung Cancer Treatments Speed Recovery), noted the growing use of personalized therapies across tumor types. The current study extends that trend to melanoma, demonstrating how bespoke mRNA vaccines can complement existing surgical and systemic treatments.

Key facts

The personalized mRNA vaccine intismeran reduced melanoma recurrence by 42% two years after surgery. (winnipegfreepress.com)
Intismeran is made with the same mRNA technology used in COVID‑19 vaccines. (nypost.com)
Dr. Hussein Tawbi of MD Anderson Cancer Center was a lead researcher on the study. (winnipegfreepress.com)
Karen Knudsen, CEO of the Parker Institute, called the result a new frontier for science. (nypost.com)